Therapeutic potential of the bactericidal/permeability-increasing protein

Expert Opinion on Investigational Drugs

Volumn 11, Issue 2, 2002, Pages 159-167

  Levy, Ofer ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

BPI; Endotoxin; Epithelia; Gram negative bacteria; Lipopolysaccharide; Neutrophil; Sepsis

Indexed keywords

BACTERICIDAL PERMEABILITY INCREASING PROTEIN; BACTERIUM LIPOPOLYSACCHARIDE; CATHELICIDIN; COMPLEMENTARY DNA; DEFENSIN; ENDOTOXIN; LIPOXIN; OPSONIN; RECOMBINANT PROTEIN; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; MEMBRANE PROTEIN; PLASMA PROTEIN;

ANTIBACTERIAL ACTIVITY; BACTEREMIA; BACTERIAL INFECTION; BINDING AFFINITY; BODY FLUID; CELL GRANULE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SAFETY; ENDOTOXEMIA; EPITHELIUM CELL; GENE EXPRESSION; GRAM NEGATIVE INFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATION; MENINGOCOCCEMIA; NEUTROPHIL; PHAGOCYTOSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW; STRUCTURE ACTIVITY RELATION; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; METABOLISM; SERUM BACTERICIDAL ACTIVITY;

ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BLOOD BACTERICIDAL ACTIVITY; BLOOD PROTEINS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; ENDOTOXINS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MEMBRANE PROTEINS; RECOMBINANT PROTEINS;

EID: 0036166334     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.2.159     Document Type: Review

References (78)

1. Phylogenetic perspectives in innate immunity
2. Gene-encoded peptide antibiotics and the concept of innate immunity: An update review
3. Innate immunity in higher insects
4. Lectures on the comparative pathology of inflammation
5. Phagocytin: A bactericidal substance from polymorphonuclear leukocytes
6. Antibacterial and enzymatic basic proteins from leukocyte lysosomes: Separation and identification
7. Partial characterization and purification of a rabbit granulocyte facotr that increases permeability of Escherichia coli
8. Neutrophil defensins: Purification, characterization, and antimicrobial testing
9. Antibiotic proteins and peptides of blood: Templates for novel antimicrobial agents
10. Antimicrobial peptides: Complementing classical inflammatory mechanisms of defence
11. Epithelial antibiotics induced at sites of inflammation
12. Paneth cells and innate immunity in the crypt microenvironment
13. Antimicrobial peptides of phagocytes and epithelia
14. Lipid mediator-induced expression of bactericidal/permeaibility-increasing protein (BPI) in human mucosal epithelia
15. Cationic peptides: Effectors in innate immunity and novel antimicrobials
16. Early and discrete changes in permeability of Escherichia coli and certain other gram-negative bacteria during killing by granulocytes
17. Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes
18. High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide
19. Cellular and subcellular localization of the bactericidal/permeability-increasing protein of neutrophils
20. Human granulocytes express a 55-kDa lipopolysaccharide-binding protein on the cell surface that is identical to the bactericidal/permeability-increasing protein
21. The bactericidal/permeability-increasing protein (BPI) is present in specific granules of human eosinophils
22. Bactericidal/permeability-increasing protein, a lipopolysaccharide-specific protein on the surface of human peripheral blood monocytes
23. Impaired innate immunity in the newborn: Newborn neutrophils are deficient in bactericidal/permeability-increasing protein (BPI)
24. Cloning of the cDNA of a human neutrophil bactericidal protein. Structural and functional correlations
25. Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution
26. Endotoxin-neutralizing properties of the 25 kD N-terminal fragment and a newly isolated 30 kD C-terminal fragment of the 55-60 kD bactericidal/permeability-increasing protein of human neutrophils
27. An opsonic function of the neutrophil bactericidal/permeability-increasing protein depends on both its N- and C-terminal domains
28. Expression and characterization of cysteine-modified variants of an amino-terminal fragment of bactericidal/permeability-increasing protein
29. Antineutrophil cytoplasm autoantibodies against bactericidal/permeability-increasing protein in inflammatory bowel disease
30. Anti-neutrophil cytoplasmic autoantibodies (ANCA) to bactericidal/permeability-increasing (BPI) protein recognize the carboxyl terminal domain
31. Preferential binding of the neutrophil cytoplasmic granule-derived bactericidal/permeability increasing protein to target bacteria. Implications and use as a means of purification
32. The three-dimensional structure of human bactericidal/permeability-increasing protein: Implications for understanding protein-lipopolysaccharide interactions
33. Separation of sublethal and lethal effects of the bactericidal/permeability increasing protein on Escherichia coli
34. Cathelicidins: A novel protein family with a common proregion and a variable C-terminal antimicrobial domain
35. Antimicrobial peptides in mammalian and insect host defence
36. Individual and synergistic effects of rabbit granulocyte proteins on Escherichia coli
37. Bacterial phospholipid hydrolysis enhances the destruction of Escherichia coli ingested by rabbit neutrophils. Role of cellular and extracellular phospholipases
38. Human bactericidal/permeability-increasing protein and a recombinant NH2-terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria
39. 21) on growth and TNF-inducing activity of Gram-negative bacteria cord blood ex vivo
40. Bactericidal/permeability-increasing protein inhibits growth of a strain of Acholeplasma laidlawii and L forms of the Gram-positive bacteria Staphyloccus aureus and streptococcus pyogenes
41. Production of antifungal recombinant peptides in Escherichia coli
42. Identification of constituents of human neutrophil azurophil granules that mediate fungistasis against histoplasma capsulatum
43. Recombinant bactericidal/permeability-increasing protein (rBPI21) in combination with sulfadiazine is active against Toxoplasma gondii
44. Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity
45. Recombinant human bactericidal/permeability-increasing protein (rBPI23) is a universal lipopolysaccharide-binding ligand
46. Mechanisms of action of the bactericidal/permeability-increasing protein BPI on endotoxin and phospholipid monolayers and aggregates
47. Lipopolysaccharide (LPS)-binding proteins BPI and LBP form different types of complexes with LPS
48. Relative concentrations of endotoxin-binding proteins in body fluids during infection
49. Competition between rBPI23, a recombinant fragment of bactericidal/permeability-increasing protein, and lipopolysaccharide (LPS)-binding protein for binding to LPS and gram-negative bacteria
50. A recombinant amino terminal fragment of bactericidal/permeability-increasing protein inhibits the induction of leukocyte responses by LPS
51. Protective effect of a recombinant amino-terminal fragment of bactericidal/permeability-increasing protein in experimental endotoxemia
52. Protective effect of a recombinant fragment of bactericidal/permeability increasing protein against carbohydrate dyshomeostasis and tumor necrosis factor-alpha elevation in rat endotoxemia
53. Protective effects of a recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in an animal model of gram-negative sepsis
54. Synergistic effect of a recombinant N-terminal fragment of bactericidal/permeability-increasing protein and cefamandole in treatment of rabbit gram-negative sepsis
55. Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans by use of recombinant bactericidal/permeability-increasing protein
56. Inhibition of endotoxin-induced activation of the coagulation and fibrinolytic pathways using a recombinant endotoxin-binding protein (rBPI23)
57. Prospects for use of recombinant BPI in the treatment of gram-negative bacterial infections
58. Bactericidal/permeability-increasing protein in host defense and its efficacy in the treatment of bacterial sepsis
59. Bactericidal/permeability-increasing protein preserves leukocyte functions after major liver resection
60. Major liver resection results in a changed plasma amino acid pattern as reflected by a decreased Fischer ratio which improves by bactericidal/permeability-increasing protein
61. 21 Acute Hemorrhagic Trauma Study Group
62. Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis
63. A Phase I safety and pharmacokinetic study of a recombinant amino terminal fragment of bactericidal/permeability-increasing protein in healthy male volunteers
64. Pharmacokinetics of a recombinant amino terminal fragment of bactericidal/permeability increasing protein (rBPI21) after liver surgery in rats and humans
65. 21) as adjunctive treatment for children with severe meningococcal sepsis: A randomised trial
66. Bactericidal/Permeability-Increasing Protein (BPI)-Lessons learned from the Phase III, randomised, clinical trial of rBPI21 for adjunctive treatment of children with severe meningococcal sepsis
67. Significance of systemic endotoxemia in inflammatory bowel disease
68. Differential alteration in intestinal epithelial cell expression of Toll-like receptor 3 (TLR3) and TLR4 in inflamamtory bowel disease
69. Adherent invasive Escherichia coli strains from patients with Crohn's disease survive and replicate within macrophages without inducing host cell death
70. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
71. Reactivation of arthritis induced by small bowel bacterial overgrowth in rats: Role of cytokines, bacteria, and bacterial polymers
72. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock
73. Tumor necrosis factor-α production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease
74. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation
75. Cell-wall-deficient bacteria and culture-negative febrile episodes in bone-marrow-transplant recipients
76. Bactericidal/permeability-increasing protein prevents mucosal damage in an experimental rat model of chronic otitis media with effusion
77. Bactericidal/permeability-increasing protein (BPI) inhibits angiogenesis via induction of apoptosis in vascular endothelial cells
78. Angiogenesis inhibition by synthetic peptides derived from bactericidal/permeability-increasing protein